Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
FCF to Net Income | 0.0% | 106.9% | 85.9% | 85.9% | 83.8% | 89.6% | 81.3% | 105.0% | 93.2% | 88.3% | 56.2% | 103.5% | 365.2% | 20.4% | 82.8% | 96.8% |
Discover the top 20 best undervalued stocks to buy for Feb 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Feb 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Feb 2025.
As of today, Microsoft Corp's last 12-month FCF to Net Income is 98.9%, based on the financial report for Sep 30, 2024 (Q3 2024). The average annual FCF to Net Income for Aadi Bioscience, Inc. have been 56.2% over the past three years, and 84.4% over the past five years.
As of today, Aadi Bioscience, Inc.'s FCF to Net Income is 98.9%, which is higher than industry median of 84.3%. It indicates that Aadi Bioscience, Inc.'s FCF to Net Income is Good.